Tardif-Samson A

Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Suite 1500, Montréal, QC, H3B 0G7, Canada.

3 papers

ArticleKetamine

Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.

Clemens K, Zhdanava M, Teeple A +6

Europe PMC2025
ArticleKetamine

Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA.

Jha MK, Zhdanava M, Shah A +4

Europe PMC2025
ArticleKetamine

Understanding profiles of patients with treatment-resistant depression by stringency of health plan prior authorization criteria for approval of esketamine nasal spray.

Harding L, Zhdanava M, Shah A +5

Europe PMC2024